Ellis responds to rumors that the procurement of fomapizone tablets has been suspended by Xiangya Second Hospital: Currently verifying the authenticity.

Regarding the circulation in the market about the suspension of the procurement of Vemurafenib Mesylate Tablets by Xiangya Second Hospital of Central South University, the securities department of Elee responded to a reporter from Caixin by phone, identifying themselves as an investor, stating that the company is currently conducting an internal verification of the authenticity of the relevant information. The related "cooperation letter" circulating in the market has its signature in the lower right corner from the hospital's medical department, and the company is still verifying whether it was officially issued by Xiangya Second Hospital. As for whether this incident will affect the future sales of Vemurafenib Mesylate Tablets, the aforementioned individual stated that the company's "operations are currently normal." They added that Vemurafenib Mesylate Tablets have had two indications renewed for inclusion in medical insurance since the beginning of this year, and new indications have been approved for marketing. "Overall, our operations are still on a relatively good trend." A cooperation letter, dated August 13 and signed by the medical department of Xiangya Second Hospital, indicated that due to the discovery of multiple pharmaceutical representatives from various companies entering the treatment areas to contact medical staff without prior appointments, the hospital has decided to suspend the procurement and use of four medications, including Elee's Vemurafenib Mesylate Tablets, with a suspension period from August 17, 2026, to November 16, 2026. A reporter from Caixin called Xiangya Second Hospital as a patient yesterday and learned that there is currently no stock of Vemurafenib Mesylate Tablets in the hospital.